Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease (COSPAR II)

This study has been completed.
Information provided by (Responsible Party):
UCB Pharma Identifier:
First received: July 25, 2006
Last updated: August 26, 2014
Last verified: April 2011
This is an open-label extension study designed to measure the safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol (CDP870) in patients with moderate to severe Crohn's disease previously enrolled in C87059 (COSPAR I, NCT00349752).

Condition Intervention Phase
Crohn's Disease
Biological: Certolizumab pegol
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Multi-center Trial to Examine the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease Previously Enrolled in C87059 (COSPAR I, NCT00349752).

Resource links provided by NLM:

Further study details as provided by UCB Pharma:

Primary Outcome Measures:
  • Occurrence of at Least One Treatment-emergent Adverse Event During This Study (Maximum 122 Weeks) [ Time Frame: During this study (maximum 122 weeks) ]
    Results are presented as the number of subjects with at least one treatment-emergent adverse event during this study.

Secondary Outcome Measures:
  • Disease Remission (Crohn's Disease Activity Index, CDAI≤150) at Week 34 in Patients Who Completed/Did Not Complete C87059 (COSPAR I, NCT00349752) and Remained Off Corticosteroids. [ Time Frame: Week 34 in this study ]
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. Results are presented as the percentage of subjects in disease remission at Week 34.

Enrollment: 106
Study Start Date: January 2007
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CDP870 400 mg
Certolizumab pegol (CDP870) 400 mg (2 injections of 1 mL) every 4 weeks from Week 2 until Week 34, or until CDP870 is available for a Crohn's disease indication in the patient's country. Subjects who were Non-completers of C87059 (COSPAR I, NCT00349752) receive an additional CDP870 400 mg dose at Week 2
Biological: Certolizumab pegol

Certolizumab pegol (CDP870), an anti-tumor necrosis factor (TNF)α, humanized antibody Fab' fragment - polyethylene glycol conjugate, solution for injection, in 10 mM sodium acetate buffer and 125 mM sodium chloride, pH 4.7, supplied in 3 mL vials with a fill of 1.4 mL (an extractable volume of 1 mL corresponds to a dose of 200 mg).

Dosing is every 4 weeks from Week 2 until Week 34, or until CDP870 is available for a Crohn's disease indication in the patient's country. Subjects who were Non-completers of C87059 (COSPAR I, NCT00349752) receive an additional CDP870 400 mg dose at Week 2.

Other Names:
  • CDP870
  • CZP
  • Cimzia


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients previously enrolled in C87059 (COSPAR I, NCT00349752)

Exclusion Criteria:

  • Subject withdrawn or discontinued from C87059 (COSPAR I, NCT00349752) study under specific conditions
  • Subject who received treatment other than study medication and other than medications permitted in C87059 (COSPAR I, NCT00349752)
  • Subjects from countries where certolizumab pegol is authorized in Crohn's disease treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00356408

  Hide Study Locations
United States, Alabama
Birmingham, Alabama, United States
Montgomery, Alabama, United States
United States, California
La Jolla, California, United States
Oceanside, California, United States
Palo Alto, California, United States
Roseville, California, United States
United States, Colorado
Lakewood, Colorado, United States
United States, Florida
Clearwater, Florida, United States
Gainesville, Florida, United States
Hialeah, Florida, United States
Jacksonville, Florida, United States
North Miami Beach, Florida, United States
United States, Georgia
Marietta, Georgia, United States
Savannah, Georgia, United States
United States, Illinois
Chicago, Illinois, United States
United States, Indiana
Bloomington, Indiana, United States
United States, Iowa
Davenport, Iowa, United States
United States, Kansas
Topeka, Kansas, United States
United States, Kentucky
Bowling Green, Kentucky, United States
Louisville, Kentucky, United States
United States, Louisiana
Metairie, Louisiana, United States
United States, Maryland
Annapolis, Maryland, United States
United States, Massachusetts
Newton, Massachusetts, United States
United States, Michigan
Chesterfield, Michigan, United States
Dearborn, Michigan, United States
Troy, Michigan, United States
United States, Minnesota
Minneapolis, Minnesota, United States
Rochester, Minnesota, United States
United States, Missouri
Kansas City, Missouri, United States
Mexico, Missouri, United States
United States, New York
New York, New York, United States
Syracuse, New York, United States
United States, North Carolina
Chapel Hill, North Carolina, United States
Charlotte, North Carolina, United States
Raleigh, North Carolina, United States
United States, Ohio
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Dayton, Ohio, United States
United States, Oklahoma
Tulsa, Oklahoma, United States
United States, South Carolina
Columbia, South Carolina, United States
United States, Tennessee
Germantown, Tennessee, United States
United States, Texas
Austin, Texas, United States
United States, Utah
Salt Lake City, Utah, United States
United States, Vermont
Burlington, Vermont, United States
United States, Virginia
Chesapeake, Virginia, United States
Richmond, Virginia, United States
United States, Washington
Seattle, Washington, United States
United States, Wisconsin
Milwaukee, Wisconsin, United States
Monroe, Wisconsin, United States
Canada, Alberta
Edmonton, Alberta, Canada
Canada, British Columbia
Abbottsford, British Columbia, Canada
Vancouver, British Columbia, Canada
Canada, Manitoba
Winnipeg, Manitoba, Canada
Canada, Nova Scotia
Halifax, Nova Scotia, Canada
Canada, Ontario
London, Ontario, Canada
Toronto, Ontario, Canada
Canada, Saskatchewan
Saskatoon, Saskatchewan, Canada
Calgary, Canada
Frankfurt, Germany
Heidelberg, Germany
Jena, Germany
Rostock, Germany
Ulm, Germany
Sponsors and Collaborators
UCB Pharma
Study Director: UCB Clinical Trial Call Center +1 877 822 9493 (UCB)
  More Information

Additional Information:
Responsible Party: UCB Pharma Identifier: NCT00356408     History of Changes
Other Study ID Numbers: C87065
2006-003871-11 ( EudraCT Number )
Study First Received: July 25, 2006
Results First Received: February 23, 2011
Last Updated: August 26, 2014

Keywords provided by UCB Pharma:
certolizumab pegol
Crohn's Disease

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Certolizumab Pegol
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents processed this record on April 26, 2017